We're proud to join our strategic collaborator, Norgine, and the broader #HepatitisDelta community at #DeltaCure2026. Bringing together the global #HDV community is critical to advancing understanding and driving progress for people living with this aggressive liver disease.

Today, we announced a multi-program collaboration and license agreement with @GileadSciences to discover and engineer novel PRO-XTEN® dual-masked #TCEs for multiple solid tumor indications. Read the press release ➡️ bit.ly/47YTstL

The U.S. @FDA granted Fast Track designation to VIR-5500, a PSMA-targeted dual-masked T-cell engager being co-developed by Astellas Pharma and #VirBiotechnology for the treatment of late-line metastatic castration-resistant prostate cancer #mCRPC. ➡️ bit.ly/4dsuczq

Join us in welcoming David Liu as EVP and CMO at #VirBiotechnology. David brings deep experience in immuno-oncology and global regulatory strategies as we pursue potentially practice-changing therapies for people with #cancer and chronic #HepatitisDelta.➡️ bit.ly/4y6dWvg

#VirBiotechnology will present expanded Phase 2 SOLSTICE results evaluating elebsiran and tobevibart in chronic #HepatitisDelta at @AASLDtweets #AASLD #TLM26 in Denver. Learn more about our two oral presentations➡️ bit.ly/3VtbPV2 #PatientsAreWaiting #HepatitisDelta

We're pleased to welcome Aziz Sawaf as EVP and CFO at #VirBiotechnology. Aziz will lead our finance, operations, IT and investor relations functions and brings more than 20 years of experience across commercial-stage and clinical development environments.➡️bit.ly/4xZYyAO

As #ProstateCancerAwarenessMonth comes to a close and we recognize #WorldCancerResearchDay, we're reminded that advancing cancer research together starts with listening to people living with cancer. Read Gregg's Stories➡️ bit.ly/4AdZ3te #AdvancingCancerResearchTogether

Gregg never imagined he would hear the words, "It's metastatic." During #ProstateCancerAwarenessMonth, he reflects on his cancer diagnosis and treatment journey. His story highlights the continued need for new treatment options. Full Stories feature ➡️ bit.ly/4AdZ3te

As we celebrate 10 years of #VirBiotechnology, we're reflecting on the people who helped shape our journey. One of our early employees, Cara Pilowa, has seen our commitment to scientific rigor remain constant through growth, innovation and transformation. #VirTurns10

Hear from our President and CEO,  Marianne De Backer, MSc, PhD, MBA, during a fireside chat at the @MorganStanley 24th Annual Global Healthcare Conference on Sept. 14 at 7:45 a.m. ET. Watch the webcast live here ➡️ bit.ly/4xB1owE #HepatitisDelta #Oncology

Our #VirBiotechnology 10-year anniversary timeline looks back on the moments that shaped the past decade, including scientific progress, company achievements, cherished traditions, and the Virites who have helped make us who we are today. Explore it here ➡️bit.ly/4ceBw12

Behind every #HepatitisDelta diagnosis is a person seeking a better outcome. If you missed our #WorldHepatitisDay Stories feature, take a moment to read this conversation with renowned hepatologist Dr. Ira Jacobson. Read more ➡️ bit.ly/4x8qgeN

As we continue to mark #VirBiotechnology's 10-year anniversary, we welcomed the families, friends and loved ones whose support helps make our work possible every day! At Vir Bio Family Day, they explored our labs, enjoyed science stories and shared meaningful time together.

To mark #WorldHepatitisDay, Virites joined the Hep B Free Hero 5K Run/Walk in San Francisco alongside advocates, families and community members dedicated to raising awareness of hepatitis, and committed to improving outcomes for people living with viral hepatitis. #HepatitisDelta

#VirBiotechnology News: We shared a corporate update and reported Q2 2026 financial results, highlighting progress across our chronic hepatitis delta (CHD) and oncology portfolios and a robust financial position of over $1.0 billion. ➡️ bit.ly/4wHocul #Earnings

Tune in today: #VirBiotechnology will share a corporate update and report Q2 2026 financial results during our investor conference call. Join us at 4:30 p.m. ET / 1:30 p.m. PT ➡️ bit.ly/4fPTY0S #Earnings

In a conversation with Dr. Ira Jacobson, a renowned hepatologist, he shares why #HepatitisDelta demands urgent attention. This #WorldHepatitisDay, let's break it down and raise awareness together with @Hep_Alliance. Read his Stories feature➡️bit.ly/45rh4Gd

👉 #VirBiotechnology will provide a corporate update and report Q2 2026 financial results on Wed., August 5, at 4:30 p.m. ET / 1:30 p.m. PT. Join our investor conference call ➡️bit.ly/4pyoWPF #Earnings

At #VirBiotechnology, we’ve built dAIsY™ into the core of our research process, combining deep biological expertise with #AI to accelerate discovery and improve the quality of the therapies we are developing. Read the full Stories feature here ➡️ bit.ly/4x7BAYz

It takes a connected healthcare ecosystem to help people living with #HepatitisDelta access care and stay linked to care. At a recent All-Hands Patient Advocacy Corner, our Chris Campbell joined Richard So of SF Hep B Free and Dr. Maurizio Bonaccini to discuss this topic.